The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

Mortality and rates of respiratory hospitalization were similar among patients with RA-ILD initiating various non-TNF inhibitor b/tsDMARDs.